Source:http://linkedlifedata.com/resource/pubmed/id/21258128
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-1-24
|
pubmed:abstractText |
Italy was the first European nation to offer free vaccination against human papillomavirus (HPV) types 16 and 18. The vaccination is actively encouraged and is available free of charge to 11-year-old girls. The introduction of new technologies such as HPV DNA testing and HPV vaccination requires cost-effectiveness analysis of cervical cancer strategies in Italy for both vaccinated and unvaccinated women.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1475-5793
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
181-9
|
pubmed:meshHeading |
pubmed-meshheading:21258128-Adult,
pubmed-meshheading:21258128-Cost-Benefit Analysis,
pubmed-meshheading:21258128-Female,
pubmed-meshheading:21258128-Humans,
pubmed-meshheading:21258128-Mass Screening,
pubmed-meshheading:21258128-Middle Aged,
pubmed-meshheading:21258128-Papillomavirus Infections,
pubmed-meshheading:21258128-Papillomavirus Vaccines,
pubmed-meshheading:21258128-Uterine Cervical Neoplasms,
pubmed-meshheading:21258128-Vaginal Smears
|
pubmed:year |
2010
|
pubmed:articleTitle |
Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis.
|
pubmed:affiliation |
Biostatistics Unit, ISPO Cancer Research and Prevention Institute, Via Cosimo il Vecchio 2, 50139 Florence, Italy. g.accetta@ispo.toscana.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|